Sgm-101
Metastasis From Malignant Tumor Of Colon
Explore 33 assets in Metastasis From Malignant Tumor Of Colon →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Leiden University Medical Center
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05965817CT.gov Fluorescence-guided Resection Of Colorectal Liver Metastases Using SGM-101 and Indocyanine GREEN | — | Unknown | — | — | — |
NCT04737213CT.gov SGM-101 in Colorectal Lung Metastases | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastasis From Malignant Tumor Of Colon
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sgm-101 (this asset) | Leiden University Medical Center | P2 | CCC · 53 |
| Fruquintinib | Peking University | P3 | BBB |
| Dexasone | Fudan University | P3 | BB |
| Oxaliplatin | Fudan University | P4 | BB |
| Capecitabine | Jun Huang | P3 | BB |
| Irinotecan | Jun Huang | P3 | BB |
| Cetuximab | Shanghai 6th People's Hospital | P3 | BB |
| Floxuridine | Fudan University | P3 | BB |
| ip-001 | Immunophotonics, Inc. | P2/3 | BB |
+42 more in the Metastasis From Malignant Tumor Of Colon cohort
Other indications for Sgm-101
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P2/3 | BB · 64 |
| Colorectal Neoplasm | — | P3 | B · 59 |
| Colorectal Cancer | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sgm-101 in Metastasis From Malignant Tumor Of Colon. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sgm-101-metastasis-from-malignant-tumor-of-colon-101932
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →